Case Studies in Modern Drug Discovery and Development

Front Cover
Xianhai Huang, Robert G. Aslanian
John Wiley & Sons, May 29, 2012 - Medical - 472 pages

Learn why some drug discovery and development efforts succeed . . . and others fail

Written by international experts in drug discovery and development, this book sets forth carefully researched and analyzed case studies of both successful and failed drug discovery and development efforts, enabling medicinal chemists and pharmaceutical scientists to learn from actual examples. Each case study focuses on a particular drug and therapeutic target, guiding readers through the drug discovery and development process, including drug design rationale, structure-activity relationships, pharmacology, drug metabolism, biology, and clinical studies.

Case Studies in Modern Drug Discovery and Development begins with an introductory chapter that puts into perspective the underlying issues facing the pharmaceutical industry and provides insight into future research opportunities. Next, there are fourteen detailed case studies, examining:

  • All phases of drug discovery and development from initial idea to commercialization

  • Some of today's most important and life-saving medications

  • Drugs designed for different therapeutic areas such as cardiovascular disease, infection, inflammation, cancer, metabolic syndrome, and allergies

  • Examples of prodrugs and inhaled drugs

  • Reasons why certain drugs failed to advance to market despite major research investments

Each chapter ends with a list of references leading to the primary literature. There are also plenty of tables and illustrations to help readers fully understand key concepts, processes, and technologies.

Improving the success rate of the drug discovery and development process is paramount to the pharmaceutical industry. With this book as their guide, readers can learn from both successful and unsuccessful efforts in order to apply tested and proven science and technologies that increase the probability of success for new drug discovery and development projects.

 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

DISCOVERY AND DEVELOPMENT OF THE DPP4 INHIBITOR JANUVIA
10
AN ANGIOTENSIN II RECEPTOR BLOCKER
45
References
64
References
85
SETTING CHAPTER 5 THE PARADIGM OF TARGETED DRUGS FOR THE TREATMENT
88
References
100
References
123
Acknowledgments
151
DISCOVERY OF ANTIMALARIAL DRUG ARTEMISININ AND BEYOND
227
References
251
DISCOVERY AND PROCESS DEVELOPMENT OF MK4965 A POTENT
257
THE FIRSTAND SECOND
296
References
330
THE FIRSTORALNONPEPTIDE
336
Acknowledgments
357
References
389

References
188
DISCOVERY AND DEVELOPMENT OF MARAVIROC A CCR5 ANTAGONIST
196
Acknowledgments
217
SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT
417
ABBREVIATIONS
432
Copyright

Other editions - View all

Common terms and phrases

About the author (2012)

Xianhai Huang, PhD, is a Principal Scientist at Merck Research Laboratories. Dr. Huang is the inventor or co-inventor on more than forty patents and patent applications. As a mentor in the Schering-Plough chemistry postdoctoral program, Dr. Huang and his group discovered novel synthetic applications of (diacetoxyiodo) benzene and successfully applied the methodology to the total synthesis of psymberin, an antitumor natural product.

Robert G. Aslanian, PhD, is an adjunct professor of chemistry at William Paterson University and was formerly a Senior Director of Medicinal Chemistry with the Schering-Plough Research Institute and Merck Research Laboratories. Dr. Aslanian has over twenty-five years of experience in the pharmaceutical industry. He is co-inventor on thirty-eight U.S. patents and coauthor on sixty-seven scientific articles and reviews.

Bibliographic information